Masayuki Masuda

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

Journal: JAMA neurology

Published: July 27, 2026

Association Between Geriatric Nutritional Risk Index and Gemcitabine Plus Nab-Paclitaxel Continuation in Elderly Patients With Pancreatic Cancer.

Association Between Geriatric Nutritional Risk Index and Gemcitabine Plus Nab-Paclitaxel Continuation in Elderly Patients With Pancreatic Cancer.

Journal: Anticancer research

Published: April 11, 2026

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Journal: Internal medicine (Tokyo, Japan)

Published: March 26, 2026

Evaluation of the Usefulness of Pharmacy Lectures to Non-pharmaceutical Students Majoring in Life Sciences: A Questionnaire Survey

Evaluation of the Usefulness of Pharmacy Lectures to Non-pharmaceutical Students Majoring in Life Sciences: A Questionnaire Survey

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: October 01, 2025

Association between Myasthenia Gravis and Smoking.

Association between Myasthenia Gravis and Smoking.

Journal: Internal medicine (Tokyo, Japan)

Published: June 11, 2025

Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.

Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.

Journal: Internal medicine (Tokyo, Japan)

Published: June 04, 2025

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Journal: Nature communications

Published: May 28, 2025

Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.

Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.

Journal: Current medical research and opinion

Published: April 28, 2025

Risk Factors for Vancomycin-Induced Nephrotoxicity and Kidney Prognosis in Patients Aged 75 Years and Older: A Retrospective Study.

Risk Factors for Vancomycin-Induced Nephrotoxicity and Kidney Prognosis in Patients Aged 75 Years and Older: A Retrospective Study.

Journal: Drugs & aging

Published: March 16, 2025

Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.

Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.

Journal: Journal of the neurological sciences

Published: February 11, 2025

Predicting achievement of clinical goals using machine learning in myasthenia gravis.

Predicting achievement of clinical goals using machine learning in myasthenia gravis.

Journal: PloS one

Published: December 23, 2024

Corrigendum to "Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology 385 (2023) 578241].

Corrigendum to "Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology 385 (2023) 578241].

Journal: Journal of neuroimmunology

Published: October 25, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026